of LH pulse amplitude throughout the 6 months after treatment suspension. Ferriman-Gallway score and ovarian vol-
INTRODUCTION
Group B was treated only with OC. Both groups were treated for 6 months and followed up for 6 months. sensitivity to GnRH stimulation (4, 8, 9) and to an 12 subjects: (a) group A: patients were treated with leuprolide acetate intramuscularly (im) (Enantone, abnormal neuromodulation of hypothalamic gonadotropin-releasing hormone (GnRH) secreting neurons 11.25 mg every 12 weeks; Takeda, Rome, Italy) plus an OC (Mercilon; Organon, Rome, Italy); and (b) (8, 10) . As a consequence of these, the altered gonadotropin release induces a reduced follicle development group B: patients were treated with only the OC. Both groups were treated for 6 months and then monitored and an abnormal ovarian steroidogenesis (2-10). Several reports have demonstrated that clinical symptoms for the following 6 months. The choice of this OC was made in order to follow previous study protocol (18) . of PCOD are dramatically reduced by the long-term administration of oral contraceptives (OC) alone or in
All patients underwent a 6-hr pulsatility study on day 7 of the menstrual cycle if eu-or oligomenorrhoic association with a variety of drugs that act on metabolism, i.e., metformin (11) or troglitazone (12) , or that before any treatment, and on day 7 of the first, third, and sixth cycle after the suspension of the therapy, are antiandrogenic, i.e., flutamide (13) or finasteride (14,15), but no dramatic changes in gonadotropins sampling every 10 min, for LH and FSH determinations. On the same days of the pulsatilities plasma secretion have been demonstrated (13) . Conversely, recently several reports described the significant effiestradiol (E 2 ), androstenedione (A), 17-hydroxyprogesterone (17-OHP), and testosterone (T) levels cacy on gonadotropin secretion of the use of GnRH agonist (GnRH-a) alone or in combination with OCs were determined. Vaginal US and the FerrimanGallway score were performed before, at the third and (16-18); since this last combined regimen was clinically effective in the restoration of a normal hypothalasixth month of therapy, at the third and sixth month after treatment suspension. Before and after 6 months mus-pituitary control of ovarian function (18) , a specific effect on gonadotropin spontaneous pulsatile of treatment lumbar bone density analysis was performed using a dual-energy photon absorptiometry release from pituitary has been supposed. On these bases, we aimed to evaluate the secretory characteriswith a Lunar DPX (Lunar Radiation, Madison, WI). The study protocol was approved by the Human tics, i.e., the spontaneous pulsatile release, of both gonadotropins in patients suffering for PCOD undergoInvestigation Committee of the University of Pisa. ing a combined treatment of GnRH-a plus an OC in comparison to those undergoing a treatment with an Assay OC alone.
All samples from each subject were assayed in duplicate in the same assay. Plasma LH and FSH concentrations were determined using an immunofluorometric MATERIALS AND METHODS assay (IFMA) previously described (19,20). All samples from the same subjects were analyzed in duplicate Subjects in tha same assay. The sensitivity of the assay expressed as the minimal detectable dose was 0.1 IU/ A group of 24 PCOD patients [mean age, 24.5 Ϯ 2.5 years (mean Ϯ SEM)] were enrolled after informed ml. The cross-reactivities with free ␣-and ␤-subunits of LH, FSH, and thyroid-stimulating hormone (TSH) consent. They were referred to our department for menstrual irregularities and/or hirsutism and acne, and were less than 2% (19). Intra-assay and interassay coefficients of variation were 4.9 and 7.4%, respecwere selected on the basis of the following criteria: (a) presence of micropolycystic ovaries at ultrasound tively. Plasma E 2 , 17-OHP, A, and T were determined by (US); (b) oligo-or amenorrhea for at least 6 months prior the study and/or chronic anovulation; (c) plasma radioimmunoassay (Radim, Pomezia, Rome, Italy) as previously described (21). Based on two quality conandrostenedione levels above the normal range for our laboratory (3.0 ng/100ml; conversion factor to pmole/ trol samples the average within-and between-assay coefficients of variation were 4.0% and 9.7% liter: 34.92) and a LH/follicle-stimulating hormone (FSH) Ͼ 2.5, (d) hirsutism and or acne (from grade mild to severe); (e) absence of any adrenal and/or other Pulse Detection and Statistical Analysis endocrine disease; and (f) no hormonal treatment in the 6 months prior the study. All patients were in a All LH and FSH time series were first evaluated separately to estimate the random measurement error range of ϩ7% to ϩ15% of their ideal body weight and the mean body mass index (BMI) was 23.5 Ϯ 1.2.
on the duplicates using the program PREDETEC.WK1 (22, 23) . Then LH and FSH secretory episodes were They were randomnly subdivided in two groups of identified using the program DETECT (23), with a P II). Six months after treatment suspension, patients of group B showed all pulsatile parameters perfectly value equal to 0.01 (1%) for the nominal false-positive rate. At the nominal P level of 0.01 (1%) for falsesimilar to baseline conditions, while patients of group A maintained an LH pulse frequency and amplitude positive errors, the false-positive rate observed on the data of the plasma pool of each subject assayed significantly lower than in baseline conditions and lower than group B (Fig. 1) . Interestingly, during the together with the time series was not statistically different from 1%.
6 months of follow-up, FSH episodic discharge showed a significant and constant reduction of pulse amplitude The presence of significant difference between groups was tested, after analysis of variance (oneonly in group A, while no changes were observed for patients of group B (Table II) . way ANOVA), using Student's t-test for paired and unpaired data, as appropriate. Linear regression analyMenstrual cyclicity was 28 Ϯ 0.8 days for group A and 34 Ϯ 2.5 days (P Ͻ 0.05) for group B (these sis was used to test correlation between individual hormonal values.
values were means over the 6 months of follow-up). Interestingly, it was more stable in group A than in group B for the entire follow-up interval (Table III) , as demonstration of a more proper activity of the repro-RESULTS ductive axis. In addition, among the patients enrolled for the combined treatment regimen, three of ten All results are showed as mean Ϯ SEM. Hormonal parameters of both groups of PCOD patients resulted remained pregnant (33.3%) in the first month after the follow-up, while no pregnancy was monitored in the similar in baseline conditions and have been reported in Table I , which shows plasma LH and FSH levels other group. Ultrasound evaluation showed the significant reducas means of the first three samples of the pulsatility. Mean BMI was perfectly similar in both groups (group tion of the ovarian volume in both groups after 6 months of treatment. Results were similar for the Ferri-A: 23.3 Ϯ 1.0; group B: 23.6 Ϯ 1.3). Before any treatment all subjects showed similar high LH and man-Gallway score, which was reduced in both groups after 6 months of treatment. Interestingly, both androgen mean plasma levels (Table I ) and gonadotropin pulsatile characteristics were perfectly superimposovarain volume and the score increased again more rapidly during the follow-up in patients of group B able (Table II) . Also, integrated LH and FSH means of the pulsatility profiles were similar (Table II) . When than group A (Fig. 2) . No changes were observed in either group in terms treatment was supended, both groups showed the significant reduction of both androgens and LH plasma of lumbar bone density after treatment suspension. levels. Indeed, on the first and third month after treatment suspension, patients of group A showed signifi-DISCUSSION cantly lower LH plasma levels, LH pulse frequency, and LH and FSH pulse amplitudes than in baseline
The present study reported the restoration of the spontaneous episodic secretion of LH and FSH during conditions and lower than patients of group B ( Table   Table I a 6-month follow-up in patients with PCOD treated tile characteristics of LH secretion immediately after treatment suspension and for a 6-month follow-up. with a combined regimen of GnRH-a plus OC in comparison to OC alone. Our study supports the specific Indeed, our data show that other than the specific positive effect of the clinical symptoms that were importance of the recovery of the spontaneous gonadotropin discharge to permit an optimal ovarian function observed during the 6 months of treatment, the specific efficacy of the combined regimen of treatment was in terms of ovulation.
PCOD has been demonstrated to have an inappropridemonstrated by the fact that during posttreatment observation interval the LH pulsatile release that ate gonadotropin secretion characterized by altered LH pulse frequency, amplitude, and LH plasma levels (3-resulted was similar to normal subjects (29) and significantly different from starting conditions as well as OC-7), and several therapeutic strategies have been suggested to treat the physiopathological situation and treated subjects. Patients treated with the combined regimen (group A) showed the reduction of both LH eliminate the anovulatory condition that is typical in PCOD patients. A variety of drugs have been used to pulse frequency and amplitude, and such changes in LH spontaneous release remained significantly lower eliminate the hyperandrogenic condition and restore ovulation (11) (12) (13) (14) (15) , but only recently a greater considfor the entire period of posttreatment observation. Conversely, patients treated with OC alone showed only eration has been given to the use of GnRH-a. In fact, several reports documented the efficacy of this coma slight reduction of LH pulse frequency within the third month of follow-up, and after 6 months all parambined regimen to induce a significant improvement of gonadotropin secretion, ovarian volume and function, eters were already similar to baseline conditions. These data give support to what previously was and ovulatory cycles (18) as well as to reduce hirsutism (16,24-27). Such a positive therapeutic effect is reported (18) and showed that the combined regimen of the 3-monthly preparation of GnRH-a plus OC gave mainly related to the pseudomenopausal condition induced by the blockade of the ovarian function and a stronger blockade on the hypothalamus-pituitary unit than the OC alone. This combined treatment perits androgen production (16). To avoid the menopausal disturbances and the possible bone resorption an estromits a better recovery of this functional unit to a normal activity, inducing the reduction of all LH pulsatile progestin preparation has been associated with GnRHa in this study as well as in others (16) (17) (18) 28) . parameters, with special regard to pulse amplitude. Indeed, this regimen also resolved the problem of the Our study for the first time documented the positive effect of the administration of GnRH-agonist, in its 3-ovarian androgen hyperproduction, since through the gonadotropin blockade it indirectly acted on the local monthly preparation, on the LH pulsatile secretion from pituitary in terms of episodic secretion and indifactors participating in the genesis of the cystic ovarian disease. Our data showed that after treatment suspenrectly on the hypothalamic function. In fact, even if other authors described the clinical efficacy of the sion the reproductive axis, namely the hypophysis, secreted lower amounts of LH with reduced pulse frecombined regimen we used, none described the pulsa- Fig. 1 . Spontaneous episodic secretion of LH and FSH for two subjects undergoing GnRH-a ϩ OC (upper panel), and to OC alone (lower panel) on day 7 of the menstrual cycle. Patient treated with the combined regimen showed a more distinct and stable recovery of the normal episodic discharge of LH for the entire period of Fig. 2 . Mean Ferriman-Gallway scores (upper panel) and mean follow-up, with a significant reduction of LH pulse amplitude and ovarian volumes (lower panel) for both groups of PCOD patients. frequency. Ⅵ baseline; ؉. 1st cycle, ᭡ 3rd cycle, ⅷ 6th cycle after Those treated with the combined regimen GnRH-a ϩ OC demontreatment suspension. strated a more stable clinical effect of the treatment during the 6 months of follow-up.
quency and amplitude only in patients treated with GnRH-a plus OC, demonstrating a greater efficacy of gonadotropin episodic discharge is essential but not enough to avoid the intrinsic propensity of these this treament in comparison to OC alone. Since patients in group A showed a slower increase of the ovarian patients to go back to their original clinical condition. This supports the hypothesis of the presence of an volumes as well as of the Ferriman-Gallway score, our data let us infer that the restoration of a normal abnormal (constitutional) peripheral (i.e., ovarian and/ or metabolic) more than central (i.e., hypothalamicendocrine control of the ovarian function; this observation was supported by not only the reduced ovarian pituitary) causal factor.
This study confirms previous reports (16-18,24) volume which remained lower than baseline in patients of group A for a longer period than group B but also that demonstrated the restoration of a more regular menstrual cyclicity and ovulation in patients undergoby the spontaneous ability to conceive that three of ten patients demonstrated as soon as they exited from ing this combined regimen and supports the fact that GnRH-a blockade of hypothalamus-pituitary function our follow-up interval.
In conclusion, the present study demonstrated that determined a positive recovery of a normal gonadotropin secretion when treatment was suspended. In addiin PCOD patients the use of a combined regimen of GnRH-a plus OC significantly modified the hypothalation, since the results we observed were in agreement with others (16-18,24), our study shows that the 3-mus-pituitary-gonadal axis activity [so that to determine a stable recovery of the reproductive axis function monthly preparation of GnRH-a is effective as is the monthly preparation. Our data suggest that the specific than using the oral contraceptive alone.] In fact, the combined regimen improved LH spontaneous release targets of action of therapeutic strategies are all the reproductive axis components. Moreover, our data throughout the posttreatment observation interval, reducing the frequency and amplitude of the spontaneconfirm that OC alone has a relatively limited effect on the overall tonic release of both gonadotropins (30), ous episodic discharge. Moreover, the use of the 3-monthly preparation of the GnRH-a was successfully and hence, on the gonadotropin-induced production of androgens from the thecainterstitial cells of the ovary similar to the monthly preparation, thus suggesting that the main advantage is the shift from a monthly to (16). This last aspect is clearly supported by the fact that OC-treated patients returned to pretreatment cona 3-monthly puncture. Our study let us infer also that patients affected by PCOD waiting for assisted reproditions at the end of the posttreatment observation interval. The present study also reveals an interesting ductive programs might try to conceive spontaneously, undergoing to a therapeutic protocol similar to the one aspect of FSH secretion. In fact, while LH showed significant changes after both kinds of treatments, FSH we used. showed only the modifications of pulse amplitude in GnRH-a-treated patients and a slight (but not significant) reduction of its plasma levels. These data seem ACKNOWLEDGMENTS to confirrm that FSH-secreting cells might have a different regulatory system and/or sensitivity as recently This study was supported in part by CNR grant proposed (31, 32 ogy, DCRT, National Institutes of Health, Bethesda, From a clinical point of view, in addition to the MD, for his helpfull suggestions and criticism. lower ovarian volumes and Ferriman-Gallway score, patients treated with the combined regimen showed a more stable intermenstrual interval in comparison to REFERENCES OC-treated subjects. This is an important aspect, since it has been demonstrated that the reproductive axis 
